Skip to main content

Advertisement

SpringerLink
Log in

Meningioma

  • Neuro-Oncology (LE Abrey, Section Editor)
  • Published:
Current Neurology and Neuroscience Reports Aims and scope Submit manuscript

Abstract

Meningiomas represent the most common primary brain tumor and comprise 3 World Health Organization (WHO) grades, the most frequent being WHO grade I (90 %). Surgery is mandatory to establish the diagnosis and to remove the tumor; however, complete resection can be achieved in only <50 % of patients. Depending on the extent of resection, tumor location and the WHO grade radiation therapy can be applied. The issue of systemic treatment such as chemotherapy or targeted therapy (eg, somatostatin receptors, antiangiogenic agents) is yet not solved, particularly as current data are derived from small uncontrolled series in patients with long-standing disease and after several pretreatments. A more thorough understanding of molecular genetics, signaling pathways and prognostic factors in meningiomas should lead to the design of studies which stratify according to these factors. These studies have to be conducted in newly diagnosed patients after incomplete resection and in tumors of WHO grade II and III.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. •• Kotecha RS, Pascoe EM, Rushing EJ, Rorke-Adams LB, Zwerdling T, Gao X, et al. Meningiomas in children and adolescents: a meta-analysis of individual patient data. Lancet Oncol. 2011;12(13):1229–39. Comprehensive review on epidemiologic and outcome data for meningiomas in children and adults.

    Article  PubMed  Google Scholar 

  2. Wiemels J, Wrensch M, Claus EB. Epidemiology and etiology of meningioma. J Neurooncol. 2010;99(3):307–14.

    Article  PubMed  Google Scholar 

  3. Oya S, Kim SH, Sade B, Lee JH. The natural history of intracranial meningiomas. J Neurosurg. 2011;114(5):1250–6.

    PubMed  Google Scholar 

  4. Nakasu S, Hirano A, Shimura T, Llena JF. Incidental meningiomas in autopsy study. Surg Neurol. 1987;27(4):319–22.

    Article  PubMed  CAS  Google Scholar 

  5. Zeidman LA, Ankenbrandt WJ, Du H, Paleologos N, Vick NA. Growth rate of non-operated meningiomas. J Neurol. 2008;255(6):891–5.

    Article  PubMed  CAS  Google Scholar 

  6. Greenberg M. Handbook of Neurosurgery. 6th ed. New York: Thieme; 2006.

    Google Scholar 

  7. Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, Jouvet A, et al. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol. 2007;114(2):97–109.

    Article  PubMed  Google Scholar 

  8. Artlich A, Schmidt D. Immunohistochemical profile of meningiomas and their histological subtypes. Hum Pathol. 1990;21(8):843–9.

    Article  PubMed  CAS  Google Scholar 

  9. Hottinger AF, Khakoo Y. Neurooncology of familial cancer syndromes. J Child Neurol. 2009;24(12):1526–35.

    Article  PubMed  Google Scholar 

  10. Zhou L, Hanemann CO. Merlin, a multi-suppressor from cell membrane to the nucleus. FEBS Lett. 2012;586(10):1403–8.

    Article  PubMed  CAS  Google Scholar 

  11. Wang X, Gong Y, Wang D, Xie Q, Zheng M, Zhou Y, et al. Analysis of gene expression profiling in meningioma: deregulated signaling pathways associated with meningioma and egfl6 overexpression in benign meningioma tissue and serum. PLoS One. 2012;7(12):e52707.

    Article  PubMed  CAS  Google Scholar 

  12. Ragel BT, Jensen RL. Aberrant signaling pathways in meningiomas. J Neurooncol. 2010;99(3):315–24.

    Article  PubMed  CAS  Google Scholar 

  13. Mawrin C, Perry A. Pathological classification and molecular genetics of meningiomas. J Neurooncol. 2010;99(3):379–91.

    Article  PubMed  CAS  Google Scholar 

  14. Gabeau-Lacet D, Aghi M, Betensky RA, Barker FG, Loeffler JS, Louis DN. Bone involvement predicts poor outcome in atypical meningioma. J Neurosurg. 2009;111(3):464–71.

    Article  PubMed  Google Scholar 

  15. Pravdenkova S, Al-Mefty O, Sawyer J, Husain M. Progesterone and estrogen receptors: opposing prognostic indicators in meningiomas. J Neurosurg. 2006;105(2):163–73.

    Article  PubMed  CAS  Google Scholar 

  16. Hasseleid BF, Meling TR, Ronning P, Scheie D, Helseth E. Surgery for convexity meningioma: Simpson Grade I resection as the goal. J Neurosurg. 2012;117(6):999–1006.

    Article  PubMed  Google Scholar 

  17. Black PM, Morokoff AP, Zauberman J. Surgery for extra-axial tumors of the cerebral convexity and midline. Neurosurgery. 2008;62(6 Suppl 3):1115–21. discussion 21–3.

    PubMed  Google Scholar 

  18. Yang SY, Park CK, Park SH, Kim DG, Chung YS, Jung HW. Atypical and anaplastic meningiomas: prognostic implications of clinicopathological features. J Neurol Neurosurg Psychiatry. 2008;79(5):574–80.

    Article  PubMed  Google Scholar 

  19. Jaaskelainen J. Seemingly complete removal of histologically benign intracranial meningioma: late recurrence rate and factors predicting recurrence in 657 patients. A multivariate analysis. Surg Neurol. 1986;26(5):461–9.

    Article  PubMed  CAS  Google Scholar 

  20. • Tseng KY, Chung MH, Sytwu HK, Lee HM, Chen KY, Chang C, et al. Osteopontin expression is a valuable marker for prediction of short-term recurrence in WHO grade I benign meningiomas. J Neurooncol. 2010;100(2):217–23. Osteopontin represents an integrin-binding protein and constitutes a prognostic factor which relates to progression-free survival within the histopathologic ‘entity’ of WHO I meningiomas.

    Article  PubMed  CAS  Google Scholar 

  21. Saloner D, Uzelac A, Hetts S, Martin A, Dillon W. Modern meningioma imaging techniques. J Neurooncol. 2010;99(3):333–40.

    Article  PubMed  CAS  Google Scholar 

  22. Omay SB, Barnett GH. Surgical navigation for meningioma surgery. J Neurooncol. 2010;99(3):357–64.

    Article  PubMed  Google Scholar 

  23. Hoover JM, Morris JM, Meyer FB. Use of preoperative magnetic resonance imaging T1 and T2 sequences to determine intraoperative meningioma consistency. Surg Neurol Int. 2011;2:142.

    Article  PubMed  Google Scholar 

  24. Osawa T, Tosaka M, Nagaishi M, Yoshimoto Y. Factors affecting peritumoral brain edema in meningioma: special histological subtypes with prominently extensive edema. J Neurooncol. 2012;111:49–57.

    Article  PubMed  Google Scholar 

  25. Regelsberger J, Hagel C, Emami P, Ries T, Heese O, Westphal M. Secretory meningiomas: a benign subgroup causing life-threatening complications. Neuro Oncol. 2009;11(6):819–24.

    Article  PubMed  Google Scholar 

  26. Qi ST, Liu Y, Pan J, Chotai S, Fang LX. A radiopathological classification of dural tail sign of meningiomas. J Neurosurg. 2012;117(4):645–53.

    Article  PubMed  Google Scholar 

  27. Jolapara M, Kesavadas C, Radhakrishnan VV, Thomas B, Gupta AK, Bodhey N, et al. Role of diffusion tensor imaging in differentiating subtypes of meningiomas. J Neuroradiol. 2010;37(5):277–83.

    Article  PubMed  CAS  Google Scholar 

  28. Chang V, Narang J, Schultz L, Issawi A, Jain R, Rock J, et al. Computeraided volumetric analysis as a sensitive tool for the management of incidental meningiomas. Acta Neurochir (Wien). 2012;154(4):589–97. discussion 97.

    Article  Google Scholar 

  29. Fathi AR, Marbacher S, Lukes A. Cost-effective patient-specific intraoperative molded cranioplasty. J Craniofac Surg. 2008;19(3):777–81.

    Article  PubMed  Google Scholar 

  30. Rubin G, Herscovici Z, Laviv Y, Jackson S, Rappaport ZH. Outcome of untreated meningiomas. Isr Med Assoc J. 2011;13(3):157–60.

    PubMed  Google Scholar 

  31. Quinones-Hinojosa A, Kaprealian T, Chaichana KL, Sanai N, Parsa AT, Berger MS, et al. Pre-operative factors affecting resectability of giant intracranial meningiomas. Can J Neurol Sci. 2009;36(5):623–30.

    PubMed  Google Scholar 

  32. Carli DF, Sluzewski M, Beute GN, van Rooij WJ. Complications of particle embolization of meningiomas: frequency, risk factors, and outcome. AJNR Am J Neuroradiol. 2010;31(1):152–4.

    Article  PubMed  CAS  Google Scholar 

  33. Afshar-Oromieh A, Giesel FL, Linhart HG, Haberkorn U, Haufe S, Combs SE, et al. Detection of cranial meningiomas: comparison of (6)(8)Ga-DOTATOC PET/CT and contrast-enhanced MRI. Eur J Nucl Med Mol Imaging. 2012;39(9):1409–15.

    Article  PubMed  Google Scholar 

  34. Gehler B, Paulsen F, Oksuz MO, Hauser TK, Eschmann SM, Bares R, et al. [68Ga]-DOTATOC-PET/CT for meningioma IMRT treatment planning. Radiat Oncol. 2009;4:56.

    Article  PubMed  Google Scholar 

  35. Thorwarth D, Muller AC, Pfannenberg C, Beyer T. Combined PET/MR imaging using (68)Ga-DOTATOC for radiotherapy treatment planning in meningioma patients. Recent Results Cancer Res. 2012;194:425–39.

    Article  Google Scholar 

  36. Sughrue ME, Rutkowski MJ, Aranda D, Barani IJ, McDermott MW, Parsa AT. Treatment decision making based on the published natural history and growth rate of small meningiomas. J Neurosurg. 2010;113(5):1036–42.

    Article  PubMed  Google Scholar 

  37. Yano S, Kuratsu J. Indications for surgery in patients with asymptomatic meningiomas based on an extensive experience. J Neurosurg. 2006;105(4):538–43.

    Article  PubMed  Google Scholar 

  38. Chamoun R, Krisht KM, Couldwell WT. Incidental meningiomas. Neurosurg Focus. 2011;31(6):E19.

    Article  PubMed  Google Scholar 

  39. Dirks MS, Butman JA, Kim HJ, Wu T, Morgan K, Tran AP, et al. Long-term natural history of neurofibromatosis Type 2-associated intracranial tumors. J Neurosurg. 2012;117(1):109–17.

    Article  PubMed  Google Scholar 

  40. Goutagny S, Bah AB, Henin D, Parfait B, Grayeli AB, Sterkers O, et al. Longterm follow-up of 287 meningiomas in neurofibromatosis type 2 patients: clinical, radiological, and molecular features. Neuro Oncol. 2012;14(8):1090–6.

    Article  PubMed  CAS  Google Scholar 

  41. Adachi K, Kawase T, Yoshida K, Yazaki T, Onozuka S. ABC Surgical Risk Scale for skull base meningioma: a new scoring system for predicting the extent of tumor removal and neurological outcome. Clinical article. J Neurosurg. 2009;111(5):1053–61.

    Article  PubMed  Google Scholar 

  42. Gerlach R, Raabe A, Scharrer I, Meixensberger J, Seifert V. Post-operative hematoma after surgery for intracranial meningiomas: causes, avoidable risk factors and clinical outcome. Neurol Res. 2004;26(1):61–6.

    Article  PubMed  Google Scholar 

  43. • Strassner C, Buhl R, Mehdorn HM. Recurrence of intracranial meningiomas: did better methods of diagnosis and surgical treatment change the outcome in the last 30 years? Neurol Res. 2009;31(5):478–82. With better operating modalities and additional treatment with radiation and gamma knife, the mortality decreased significantly from 12 % to 3 % and the outcome of the patients is still improving, so that even elderly patients can undergo surgical treatment with minor risks.

    Article  PubMed  Google Scholar 

  44. Al-Mefty O, Holoubi A, Rifai A, Fox JL. Microsurgical removal of suprasellar meningiomas. Neurosurgery. 1985;16(3):364–72.

    Article  PubMed  CAS  Google Scholar 

  45. Kim EH, Cho JM, Chang JH, Kim SH, Lee KS. Application of intraoperative indocyanine green videoangiography to brain tumor surgery. Acta Neurochir (Wien). 2011;153(7):1487–95. discussion 94–5.

    Article  Google Scholar 

  46. Coluccia D, Fandino J, Fujioka M, Cordovi S, Muroi C, Landolt H. Intraoperative 5-aminolevulinic-acid-induced fluorescence in meningiomas. Acta Neurochir (Wien). 2010;152(10):1711–9.

    Article  Google Scholar 

  47. Bekelis K, Valdes PA, Erkmen K, Leblond F, Kim A, Wilson BC, et al. Quantitative and qualitative 5-aminolevulinic acid-induced protoporphyrin IX fluorescence in skull base meningiomas. Neurosurg Focus. 2011;30(5):E8.

    PubMed  Google Scholar 

  48. Soleman J, Fathi AR, Marbacher S, Fandino J. The role of intraoperative magnetic resonance imaging in complex meningioma surgery magnetic resonance imaging. Magnetic Resonance Imaging. 2012;In Press [accepted].

  49. Solheim O, Selbekk T, Lindseth F, Unsgard G. Navigated resection of giant intracranial meningiomas based on intraoperative 3D ultrasound. Acta Neurochir (Wien). 2009;151(9):1143–51.

    Article  Google Scholar 

  50. Marbacher S, Coluccia D, Fathi AR, Andereggen L, Beck J, Fandino J. Intraoperative patient-specific reconstruction of partial bone flap defects after convexity meningioma resection. World Neurosurg. 2013;79(1):124–30.

    Article  PubMed  Google Scholar 

  51. Dehdashti AR, Ganna A, Witterick I, Gentili F. Expanded endoscopic endonasal approach for anterior cranial base and suprasellar lesions: indications and limitations. Neurosurgery. 2009;64(4):677–87. discussion 87–9.

    Article  PubMed  Google Scholar 

  52. Fatemi N, Dusick JR, de Paiva Neto MA, Malkasian D, Kelly DF. Endonasal versus supraorbital keyhole removal of craniopharyngiomas and tuberculum sellae meningiomas. Neurosurgery. 2009;64(5 Suppl 2):269–84. discussion 84–6.

    PubMed  Google Scholar 

  53. Komotar RJ, Starke RM, Raper DM, Anand VK, Schwartz TH. Endoscopic endonasal versus open transcranial resection of anterior midline skull base meningiomas. World Neurosurg. 2012;77(5–6):713–24.

    Article  PubMed  Google Scholar 

  54. Schroeder HW, Hickmann AK, Baldauf J. Endoscope-assisted microsurgical resection of skull base meningiomas. Neurosurg Rev. 2011;34(4):441–55.

    Article  PubMed  Google Scholar 

  55. Bledsoe JM, Link MJ, Stafford SL, Park PJ, Pollock BE. Radiosurgery for large-volume (> 10 cm3) benign meningiomas. J Neurosurg. 2010;112(5):951–6.

    Article  PubMed  Google Scholar 

  56. Bloch O, Kaur G, Jian BJ, Parsa AT, Barani IJ. Stereotactic radiosurgery for benign meningiomas. J Neurooncol. 2012;107(1):13–20.

    Article  PubMed  Google Scholar 

  57. Flannery TJ, Kano H, Lunsford LD, Sirin S, Tormenti M, Niranjan A, et al. Long-term control of petroclival meningiomas through radiosurgery. J Neurosurg. 2010;112(5):957–64.

    Article  PubMed  Google Scholar 

  58. Astner ST, Theodorou M, Dobrei-Ciuchendea M, Auer F, Kopp C, Molls M, et al. Tumor shrinkage assessed by volumetric MRI in the long-term follow-up after stereotactic radiotherapy of meningiomas. Strahlenther Onkol. 2010;186(8):423–9.

    Article  PubMed  Google Scholar 

  59. Kondziolka D, Madhok R, Lunsford LD, Mathieu D, Martin JJ, Niranjan A, et al. Stereotactic radiosurgery for convexity meningiomas. J Neurosurg. 2009;111(3):458–63.

    Article  PubMed  Google Scholar 

  60. Kondziolka D, Mathieu D, Lunsford LD, Martin JJ, Madhok R, Niranjan A, et al. Radiosurgery as definitive management of intracranial meningiomas. Neurosurgery. 2008;62(1):53–8. discussion 8–60.

    Article  PubMed  Google Scholar 

  61. Stessin AM, Schwartz A, Judanin G, Pannullo SC, Boockvar JA, Schwartz TH, et al. Does adjuvant external-beam radiotherapy improve outcomes for nonbenign meningiomas? A Surveillance, Epidemiology, and End Results (SEER)-based analysis. J Neurosurg. 2012;117(4):669–75.

    Article  PubMed  Google Scholar 

  62. Askoxylakis V, Zabel-du Bois A, Schlegel W, Debus J, Huber P, Milker-Zabel S. Patterns of failure after stereotactic radiotherapy of intracranial meningioma. J Neurooncol. 2010;98(3):367–72.

    Article  PubMed  Google Scholar 

  63. Attia A, Chan MD, Mott RT, Russell GB, Seif D, Daniel Bourland J, et al. Patterns of failure after treatment of atypical meningioma with gamma knife radiosurgery. J Neurooncol. 2012;108(1):179–85.

    Article  PubMed  Google Scholar 

  64. •• Santacroce A, Walier M, Regis J, Liscak R, Motti E, Lindquist C, et al. Longterm tumor control of benign intracranial meningiomas after radiosurgery in a series of 4565 patients. Neurosurgery. 2012;70(1):32–9. discussion 9. One of the largest series with gamma knife treatment of benign meningiomas (5300 treated tumors) reported on 5- and 10-year progression-free survival rates of 95.2 % and 88.6 %, respectively.

    Article  PubMed  Google Scholar 

  65. Henze M, Dimitrakopoulou-Strauss A, Milker-Zabel S, Schuhmacher J, Strauss LG, Doll J, et al. Characterization of 68Ga-DOTA-D-Phe1-Tyr3-octreotide kinetics in patients with meningiomas. J Nucl Med. 2005;46(5):763–9.

    PubMed  CAS  Google Scholar 

  66. Schulz S, Pauli SU, Handel M, Dietzmann K, Firsching R, Hollt V. Immunohistochemical determination of five somatostatin receptors in meningioma reveals frequent overexpression of somatostatin receptor subtype sst2A. Clin Cancer Res. 2000;6(5):1865–74.

    PubMed  CAS  Google Scholar 

  67. Florio T. Molecular mechanisms of the antiproliferative activity of somatostatin receptors (SSTRs) in neuroendocrine tumors. Front Biosci. 2008;13(1):822–40.

    Article  PubMed  CAS  Google Scholar 

  68. Bruns C, Lewis I, Briner U, Meno-Tetang G, Weckbecker G. SOM230: a novel somatostatin peptidomimetic with broad somatotropin release inhibiting factor (SRIF) receptor binding and a unique antisecretory profile. Eur J Endocrinol. 2002;146(5):707–16.

    Article  PubMed  CAS  Google Scholar 

  69. Bartolomei M, Bodei L, De Cicco C, Grana CM, Cremonesi M, Botteri E, et al. Peptide receptor radionuclide therapy with (90)Y-DOTATOC in recurrent meningioma. Eur J Nucl Med Mol Imaging. 2009;36(9):1407–16.

    Article  PubMed  CAS  Google Scholar 

  70. • Kreissl MC, Hanscheid H, Lohr M, Verburg FA, Schiller M, Lassmann M, et al. Combination of peptide receptor radionuclide therapy with fractionated external beam radiotherapy for treatment of advanced symptomatic meningioma. Radiat Oncol. 2012;7:99. ‘Upfront’ use of 177 Lu-DOTATOC in newly diagnosed meningioma WHO I.

    Article  PubMed  CAS  Google Scholar 

  71. Mason WP, Gentili F, Macdonald DR, Hariharan S, Cruz CR, Abrey LE. Stabilization of disease progression by hydroxyurea in patients with recurrent or unresectable meningioma. J Neurosurg. 2002;97(2):341–6.

    Article  PubMed  CAS  Google Scholar 

  72. Chamberlain MC. Hydroxyurea for recurrent surgery and radiation refractory high-grade meningioma. J Neurooncol. 2012;107(2):315–21.

    Article  PubMed  CAS  Google Scholar 

  73. Chamberlain MC, Tsao-Wei DD, Groshen S. Temozolomide for treatmentresistant recurrent meningioma. Neurology. 2004;62(7):1210–2.

    Article  PubMed  CAS  Google Scholar 

  74. Goodwin JW, Crowley J, Eyre HJ, Stafford B, Jaeckle KA, Townsend JJ. A phase II evaluation of tamoxifen in unresectable or refractory meningiomas: a Southwest Oncology Group study. J Neurooncol. 1993;15(1):75–7.

    Article  PubMed  CAS  Google Scholar 

  75. Grunberg SM, Weiss MH, Russell CA, Spitz IM, Ahmadi J, Sadun A, et al. Long-term administration of mifepristone (RU486): clinical tolerance during extended treatment of meningioma. Cancer Invest. 2006;24(8):727–33.

    Article  PubMed  CAS  Google Scholar 

  76. Chamberlain MC, Glantz MJ, Fadul CE. Recurrent meningioma: salvage therapy with long-acting somatostatin analogue. Neurology. 2007;69(10):969–73.

    Article  PubMed  CAS  Google Scholar 

  77. Johnson DR, Kimmel DW, Burch PA, Cascino TL, Giannini C, Wu W, et al. Phase II study of subcutaneous octreotide in adults with recurrent or progressive meningioma and meningeal hemangiopericytoma. Neuro Oncol. 2011;13(5):530–5.

    Article  PubMed  CAS  Google Scholar 

  78. Nayak L, Iwamoto FM, Rudnick JD, Norden AD, Lee EQ, Drappatz J, et al. Atypical and anaplastic meningiomas treated with bevacizumab. J Neurooncol. 2012;109(1):187–93.

    Article  PubMed  CAS  Google Scholar 

  79. Lou E, Sumrall AL, Turner S, Peters KB, Desjardins A, Vredenburgh JJ, et al. Bevacizumab therapy for adults with recurrent/progressive meningioma: a retrospective series. J Neurooncol. 2012;109(1):63–70.

    Article  PubMed  CAS  Google Scholar 

  80. Horak P, Wohrer A, Hassler M, Hainfellner J, Preusser M, Marosi C. Imatinib mesylate treatment of recurrent meningiomas in preselected patients: a retrospective analysis. J Neurooncol. 2012;109(2):323–30.

    Article  PubMed  CAS  Google Scholar 

  81. Norden AD, Raizer JJ, Abrey LE, Lamborn KR, Lassman AB, Chang SM, et al. Phase II trials of erlotinib or gefitinib in patients with recurrent meningioma. J Neurooncol. 2010;96(2):211–7.

    Article  PubMed  CAS  Google Scholar 

Download references

Disclosure

Ali-Reza Fathi declares no conflict of interest. Ulrich Roelcke declares no conflict of interest.

Author information

Authors and Affiliations

  1. Department of Neurosurgery, Cantonal Hospital, 5001, Aarau, Switzerland

    Ali-Reza Fathi

  2. Department of Neurology & Brain Tumor Center, Cantonal Hospital, 5001, Aarau, Switzerland

    Ulrich Roelcke

  3. University of Basel, School of Medicine, 4031, Basel, Switzerland

    Ulrich Roelcke

Authors
  1. Ali-Reza Fathi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ulrich Roelcke
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ulrich Roelcke.

Additional information

This article is part of the Topical Collection on Neuro-Oncology

Rights and permissions

Reprints and permissions

About this article

Cite this article

Fathi, AR., Roelcke, U. Meningioma. Curr Neurol Neurosci Rep 13, 337 (2013). https://doi.org/10.1007/s11910-013-0337-4

Download citation

  • Published:

  • DOI: https://doi.org/10.1007/s11910-013-0337-4

Keywords

Search

Navigation